#22 - Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins

#22 - Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins

0 Umsagnir
0
Episode
23 of 423
Lengd
1Klst. 4Mín.
Tungumál
enska
Gerð
Flokkur
Sjálfsrækt

In this five-part series, Thomas Dayspring, M.D., FACP, FNLA, a world-renowned expert in lipidology, and one of Peter's most important clinical mentors, shares his wealth of knowledge on the subject of lipids. In Part III, Peter and Tom dig into HDL, why "reverse cholesterol transport" is a lot more nuanced than what most of us are taught, lipid transport, apolipoproteins, and more. In addition, this episode highlights the complexity of HDL and a discussion about the CETP inhibitor trials. We discuss: • Reverse cholesterol transport [1:40]; • Lipid transportation, apolipoproteins, VLDL, IDL, and LDL particles [11:00]; • Remnant lipoproteins and apoC-III [16:45]; • Particles having sex: lipid exchange [28:00]; • Cholesteryl Ester Transfer Protein (CETP) and CETP inhibitors [40:45]; • 2006 CETP inhibitor trial: torcetrapib (Pfizer) [54:45]; • 2012 CETP inhibitor trial: dalcetrapib (Hoffmann–La Roche) [56:15]; • 2017 CETP inhibitor trials: evacetrapib (Eli Lilly) and anacetrapib (Merck) [58:00]; and • More. Learn more at www.PeterAttiaMD.com Connect with Peter on Facebook | Twitter | Instagram.


Hlustaðu og lestu

Stígðu inn í heim af óteljandi sögum

  • Lestu og hlustaðu eins mikið og þú vilt
  • Þúsundir titla
  • Getur sagt upp hvenær sem er
  • Engin skuldbinding
Prófa frítt
is Device Banner Block 894x1036
Cover for #22 - Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins

Other podcasts you might like ...